Helen Hoffmann
YOU?
Author Swipe
View article: Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients
Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients Open
Introduction In severe COVID-19, direct-acting antiviral drugs were not effective in hyperinflammatory stages and steroid treatment may weaken host immunity. The MEK inhibitor zapnometinib, as a host-targeting drug, has demonstrated promis…
View article: Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2
Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2 Open
The recent COVID-19 pandemic again highlighted the urgent need for broad-spectrum antivirals, both for therapeutic use in acute viral infection and for pandemic preparedness in general. The targeting of host cell factors hijacked by viruse…
View article: Analyzing Trends in Material Culture Evolution—a Case Study of Gravettian Points from Lower Austria and Moravia
Analyzing Trends in Material Culture Evolution—a Case Study of Gravettian Points from Lower Austria and Moravia Open
Identifying, analyzing, and explaining trends in the development of material culture is one of the major concerns in prehistoric archaeology. The traditional recording of data in typologies, however, is not optimal for answering the questi…
View article: The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses
The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses Open
Coronavirus disease 2019 (COVID-19), the illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to more than 260 million confirmed infections and 5 million deaths to date. Whi…
View article: Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups Open
We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to…
View article: Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX® and BacterX® Pro
Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX® and BacterX® Pro Open
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic effects daily dental work. Therefore, infection control measures are necessary to prevent infection of dental personnel during dental treatments. The use of a prepro…
View article: Designing a therapeutic SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups
Designing a therapeutic SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups Open
Here, we describe the preliminary results of an experimental vaccination of a self-experimenting healthy volunteer with eight SARS-CoV-2-derived peptides: five predicted to bind to HLA class I molecules (CD8 peptides) and three predicted t…